Biomea Fusion to present diabetes drug icovamenib data at ADA 2026 conference

Biomea Fusion announced that three abstracts on its investigational diabetes drug icovamenib will be presented at the American Diabetes Association's 86th Scientific Sessions in June 2026. The data highlights icovamenib's potential to improve beta cell function and metabolic health in both type 1 and type 2 diabetes patients. Icovamenib is an oral menin inhibitor in Phase 2 trials, aiming to restore insulin production by targeting beta cell dysfunction. These presentations could advance understanding of new treatment options for diabetes management.